Sempra outbids Buffett for Oncor, Fiat Chrysler soars, Nike gets downgraded
| Previous Close | 77.07 |
| Open | 77.12 |
| Bid | 77.33 x 200 |
| Ask | 77.34 x 200 |
| Day's Range | 76.89 - 77.63 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 1,623,301 |
| Avg. Volume | 3,606,988 |
| Market Cap | 80.86B |
| Beta | 0.15 |
| PE Ratio (TTM) | 37.34 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.70%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Barrons.com•3 days ago
Eli Lilly: Can Sales Grow Without M&A?
Can Eli Lilly (LLY) deliver the revenue growth it promised Wall Street? It was last summer when the drug maker set a target for 5% average annual sales growth for the five-year period ending in 2020. Now, Morgan Stanley David Risinger says Lilly can hit its growth goal, but only if it makes some acquisitions.
- Market Realist•3 days ago
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.
- Barrons.com•4 days ago
Eli Lilly: Will A New Rival Hobble Its Top Growth Driver?
The Danish drug maker is the world’s largest manufacturer of insulin. Late yesterday, the company unveiled data from the Sustain-7 trial that shows its diabetes treatment semaglutide bested a competing treatment made by Eli Lilly (LLY) in controlling blood sugar levels and aiding in weight loss. Evercore ISI’s Umer Raffat called it a “best case outcome” for Novo Nordisk.
